Active, not recruitingPhase 4NCT06780332
Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq
Studying Classic phenylketonuria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BioMarin Pharmaceutical
- Principal Investigator
- Medical Director, MD, M.DBioMarin Pharmaceutical
- Intervention
- RDD to Palynziq(drug)
- Enrollment
- 9 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2025
Study locations (1)
- Uncommon Cures, Chevy Chase, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06780332 on ClinicalTrials.govOther trials for Classic phenylketonuria
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07241234A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With PhenylketonuriaAgios Pharmaceuticals, Inc.
- RECRUITINGNANCT07526909Effect of Different Meal Types Given Before Exercise on Plasma Amino Acid Levels and Metabolic Control Parameters in Classical Phenylketonuria Patients Undergoing Aerobic and Resistance ExercisesHacettepe University
- RECRUITINGNANCT01659749Educational, Social Support, and Nutritional Interventions and Their Cumulative Effect on Pregnancy Outcomes and Quality of Life in Teen and Adult Women With PhenylketonuriaEmory University